文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

局限期前列腺癌2次与5次立体定向消融放疗的生活质量分析

Two versus five stereotactic ablative radiotherapy treatments for localized prostate cancer: A quality of life analysis of two prospective clinical trials.
PubMed 文献 · Radiother Oncol · 2019-06-29

该研究比较两项II期临床试验中2次与5次立体定向消融放疗(SABR)治疗低危或中危前列腺癌的生活质量。结果显示2次SABR组肠道领域平均生活质量随时间显著更优(p=0.0004),肠道和性功能最小临床重要改变发生率显著更低,但需要随机试验确认。

要点

  • 2次SABR组肠道领域平均生活质量随时间显著优于5次组(p=0.0004)。
  • 2次组肠道MCIC发生率显著更低(17.8% vs 42.3%,p=0.01)。
  • 2次组性功能MCIC×2发生率显著更低(0 vs 17.6%,p=0.01)。

核心结论

  • 2次SABR可行且耐受性良好,在肠道和性功能生活质量方面显示出显著改善信号。

研究设计与样本

  • 两项II期临床试验的生活质量分析,纳入低危或中危前列腺癌患者,分别接受26 Gy/2次和40 Gy/5次SABR。

主要发现

  • 2次组和5次组分别有30例和152例患者,中位随访55和62个月,5年生化失败率分别为3.3%和4.6%。
  • 2次组肠道领域平均生活质量随时间显著更优(p=0.0004),泌尿和性功能领域无显著差异。
  • 2次组肠道MCIC发生率显著更低(17.8% vs 42.3%,p=0.01),泌尿(24.1% vs 35.7%)和性功能(15.3% vs 29.2%)MCIC无差异。
  • MCIC×2时,2次组肠道(7.1% vs 24%,p=0.04)和性功能(0 vs 17.6%,p=0.01)MCIC发生率均显著更低。

关键数值与推荐

  • MCIC定义为>0.5个标准差,MCIC×2代表中度生活质量改变。

临床怎么用

  • 2次SABR可作为局限期前列腺癌的可行治疗选择,且可能改善肠道和性功能生活质量。

局限性

  • 非随机比较,样本量不对称(2次组30例 vs 5次组152例),需随机试验确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Stereotactic ablative radiotherapy (SABR) is appealing for prostate cancer (PCa) due to low α/β, and increasing the dose per fraction could improve the therapeutic index and lead to a better quality of life (QOL). Here we report the outcomes of a QOL comparison between two phase II clinical trials: two vs. five fraction prostate SABR. METHODS: Patients had low or intermediate risk PCa. The doses prescribed were 26 Gy/2 and 40 Gy/5. Expanded prostate cancer index composite was collected. Urinary, bowel and sexual domains were analyzed. Minimal clinically important change (MCIC) was defined as >0.5 standard deviation. RESULTS: 30 and 152 patients were treated with 2-fraction and 5-fraction SABR. Median follow-up was 55 and 62 months. Five-year biochemical failure rate was 3.3% and 4.6%. The 2-fraction cohort had a significantly better mean QOL over time in the bowel domain (p = 0.0004), without a significant difference in the urinary or sexual domains. The 2-fraction cohort had a significantly lower rate of bowel MCIC (17.8% vs 42.3%, p = 0.01), but there was no difference in urinary (24.1% vs 35.7%) or sexual (15.3% vs 29.2%) MCIC. For MCIC x2 (moderate QOL change), the 2-fraction trial had significantly lower MCIC rates in both the bowel (7.1% vs 24%, p = 0.04) and sexual (0 vs 17.6%, p = 0.01) domains. CONCLUSIONS: 2-Fraction SABR is feasible to deliver and well tolerated, with significant signals of improved bowel and sexual QOL. A randomized trial of two vs. five fractions for prostate SABR is needed to confirm the promising findings of this study.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Alayed Y, Quon H, Cheung P, et al. Two versus five stereotactic ablative radiotherapy treatments for localized prostate cancer: A quality of life analysis of two prospective clinical trials. Radiother Oncol. 2019. PMID: 31265940. doi:10.1016/j.radonc.2019.06.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。